DOCSLIB.ORG

Fiscal Year 2006/2007 Office of Research University of South Florida

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fiscal Year 2006/2007 Office of Research University of South Florida REPORT OF RESEARCH ACTIVITIES Fiscal Year 2006/2007 Office of Research University of South Florida December 2007 Office of Research University of South Florida 30338 USF Holly Drive Tampa, Florida 33620-3033 Phone: 813-974-5570 Fax: 813-974-3348 Email: [email protected] This document is also available on the USF Office of Research Web site at www.research.usf.edu FY06/07 TABLE OF CONTENTS SECTION 1 . 1-6 z Contact Information { Office of Research { Research Technologies { Research Resources { Sponsored Research { Research Integrity and Compliance { Comparative Medicine { Technology Development { Patents & Licensing { USF Research Foundation z Office of Research Web Site http://www.research.usf.edu z Research Activity Reports http://reports.research.usf.edu SECTION 2 . 7- 50 z Awards Data SECTION 3 . 51-186 z Project Awards: Detailed Funding SECTION 4 . 187-202 z Non-Project Awards: Detailed Funding SECTION 5 . 203-218 z Internal Awards Programs { Program Overview { Research Council Members { 2006 - 2007 Awards Table { Five-Year Summary { Detailed Funding SECTION 6 . 219-225 z Proposal Data UNIVERSITY OF SOUTH FLORIDA OFFICE OF RESEARCH REPORT OF RESEARCH ACTIVITIES FISCAL YEAR 2006/2007 SECTION 1 CONTACTS 1 2 Organizational and Contact Information as June 30, 2007 Office of Research Chang, Ph.D., Robert [email protected] (813) 974-5481 Vice President for Research Pope, Priscilla [email protected] (813) 974-2897 Associate Vice President Casto, Ph.D., Rod [email protected] (813) 974-1082 Associate Vice President for Economic Development Research Technologies Skinner, Rick [email protected] (813) 974-5569 Director, Research Technologies Research Resources Puig, Rebecca [email protected] (813) 974-5465 Director Sponsored Research Pope, Priscilla [email protected] (813) 974-2897 Associate Vice President Gentilini, Jane [email protected] (813) 974-5284 Coordinator, Research Programs/Services Research Integrity and Compliance Bercu, Barry [email protected] (813) 974-5638 Chair, Biomedical IRBs Dent, William [email protected] (813) 974-5018 USF Diving Safety Officer Ellwood, Archie [email protected] (813) 974-5110 Scientific Research Manager 3 Epley, Norma [email protected] (813) 974-3234 Assistant Director, Research Programs Freeman, Dennis [email protected] (813) 974-7104 Director Fultz-Carver, Caroline [email protected] (813) 974-9312 Assistant Director, Quality Assurance Program Moulvi, Farah [email protected] (813) 974-0954 IACUC/Bio Safety Officer Stiles, Paul [email protected] (813) 974-5638 Chair, IRB Social/Behavioral Studies Weaver, Adam [email protected] (813) 974-1194 USF Radiation Safety Officer Witanachchi, Vinita [email protected] (813) 974-5478 Research Privacy Coordinator Zych, Henry [email protected] (813) 974-7454 IRB Coordinator Comparative Medicine Combast, Amy [email protected] (813) 745-6743 Coordinator, Administrative Services Engelman, Robert [email protected] (813) 745-6852 Associate Professor and Director Graham, Lloyd [email protected] (813) 974-9876 Coordinator Research Programs/Services Owens, Una [email protected] (813) 745-3919 Assistant Director Trahan, Creighton J [email protected] (813) 974-9260 Associate Director 4 Van Etten, James [email protected] (813) 974-9842 Research Associate Technology Development Casto, Ph.D., Rod [email protected] (813) 974-1082 Associate Vice President Madden, Allison [email protected] (813) 974-5095 CFO & Associate Director Research Foundation McDevitt, Valerie [email protected] (813) 974-2466 Director, Patents & Licensing Patents & Licensing Casto, Ph.D., Rod [email protected] (813) 974-1082 Associate Vice President Johnson, Tricia [email protected] (813) 974-7412 Manager, Technology Agreements McDevitt, Valerie [email protected] (813) 974-2466 Director Whitley, Kathy [email protected] (813) 974-8963 Manager of Information Resources USF Research Foundation Carlucci, Carl [email protected] (813) 974-4903 President Casto, Ph.D., Rod [email protected] (813) 974-1082 Associate Vice President & Executive Director Madden, Allison [email protected] (813) 974-5095 CFO & Associate Director 5 6 UNIVERSITY OF SOUTH FLORIDA OFFICE OF RESEARCH REPORT OF RESEARCH ACTIVITIES FISCAL YEAR 2006/2007 SECTION 2 AWARDS DATA 7 8 Office of Research Annual Report 2006/2007 Section 2 Awards Data AWARDS SUMMARY FISCAL YEAR 2006/2007 COLLEGE/AREA AMOUNT ACADEMIC AFFAIRS $ 7,030,080 SCHOOL OF ARCHITECTURE & COMMUNITY DESIGN 1,448,641 COLLEGE OF ARTS AND SCIENCES 27,368,761 COLLEGE OF BUSINESS ADMINISTRATION 1,691,312 COLLEGE OF EDUCATION 20,369,845 COLLEGE OF ENGINEERING 22,799,158 COLLEGE OF MARINE SCIENCE 20,827,663 COLLEGE OF VISUAL AND PERFORMING ARTS 305,446 FLORIDA MENTAL HEALTH INSTITUTE 28,666,666 HONORS COLLEGE 93,055 COLLEGE OF MEDICINE 134,806,130 COLLEGE OF NURSING 1,309,256 COLLEGE OF PUBLIC HEALTH 19,703,225 USF LAKELAND 210,863 USF SARASOTA/MANATEE 133,102 USF ST. PETERSBURG 1,805,594 OFFICE OF RESEARCH 8,000,000 OFFICE OF THE PRESIDENT 481,585 STUDENT AFFAIRS 279,318 UNIVERSITY ADVANCEMENT 6,821,945 UNIVERSITY SERVICES 4,277,633 TOTAL FUNDING $ 308,429,278 9 Office of Research Annual Report 2006/2007 Section 2 Awards Data TOTAL AWARDS DIVISION OF SPONSORED RESEARCH FISCAL YEAR 2006/2007 Agency/Class Research Training Other Total Federal Government $ 100,305,647 $ 12,522,935 $ 9,105,604 $ 121,934,186 40% State/Local Government $ 45,898,612 $ 25,840,012 $ 21,959,908 $ 93,698,531 30% Private Partnerships $ 20,840,568 $ 3,750,137 $ 68,205,857 $ 92,796,561 30% Totals $ 167,044,826 $ 42,113,084 $ 99,271,369 $ 308,429,278 Research Awards by Funding Type Private Partnerships 30% State/Local Government 30% Federal Government 40% 10 Office of Research Annual Report 2006/2007 Section 2 Awards Data AWARDS BY PROJECT TYPE Other 32% Research 54% Training 14% Agency/Class Research Training Other Total $167,044,826 $42,113,084 $99,271,369 $308,429,279 11 Office of Research Annual Report 2006/2007 Section 2 Awards Data Category 96/97 97/98 98/99 99/00 00/01 01/02 02/03 03/04 04/05 05/06 06/07 Federal % 27% 31% 31% 31% 45% 49% 48% 44% 47% 48% 40% Federal $28.9 $41.5 $50.3 $53.7 $84.1 $101.9 $122.7 $128.0 $134.5 $149.3 121.9 Total $106.0 $134.9 $161.3 $171.3 $186.2 $207.9 $254.8 $290.1 $287.2 $310.2 $308.4 RESEARCH AWARDS $350 $300 $250 M i l $200 l i o $150 n s $100 $50 $0 96/97 97/98 98/99 99/00 00/01 01/02 02/03 03/04 04/05 05/06 06/07 Federal % 27% 31% 31% 31% 45% 49% 48% 44% 47% 48% 40% Federal $28.9 $41.5 $50.3 $53.7 $84.1 $101.9 $122.7 $128.0 $134.5 $149.3 121.9 Total $106.0 $134.9 $161.3 $171.3 $186.2 $207.9 $254.8 $290.1 $287.2 $310.2 $308.4 12 Office of Research Annual Report 2006/2007 Section 2 Awards Data AWARDS BY COLLEGE/AREA FOUR-YEAR SUMMARY College/Area FY02/03 FY03/04 FY04/05 FY05/06 FY06/07 ACADEMIC AFFAIRS$ 3,809,380 $ 2,987,320 $ 10,884,630 $ 3,658,463 $ 7,030,080 COLLEGE OF ARTS AND SCIENCES 16,727,468 19,589,544 19,408,482 23,438,314 27,368,761 COLLEGE OF BUSINESS ADMINISTRATION 1,395,175 2,074,912 2,135,490 2,053,212 1,691,312 COLLEGE OF EDUCATION 25,303,278 23,230,972 28,890,812 16,096,104 20,369,845 COLLEGE OF ENGINEERING 25,251,806 22,001,050 24,196,403 27,833,020 22,799,158 COLLEGE OF MARINE SCIENCE 24,926,303 23,907,668 15,262,737 19,922,252 20,827,663 COLLEGE OF MEDICINE 88,159,061 116,476,131 111,715,595 144,150,419 134,806,130 COLLEGE OF NURSING 2,574,576 2,668,651 1,693,117 3,966,524 1,309,256 COLLEGE OF PUBLIC HEALTH 29,001,973 25,192,814 19,337,432 16,113,696 19,703,225 COLLEGE OF VISUAL AND PERFORMING ARTS 154,233 179,348 201,153 202,542 305,446 FLORIDA MENTAL HEALTH INSTITUTE 24,067,454 28,556,289 31,335,320 30,393,141 28,666,666 HONORS COLLEGE - - - - 93,055 NEW COLLEGE 33,949 452,000 - - - OFFICE OF RESEARCH 100,000 6,170,825 5,009,605 1,964,130 8,000,000 OFFICE OF THE PRESIDENT 166,598 144,047 184,465 151,430 481,585 SCHOOL OF ARCHITECTURE & COMMUNITY DESIGN 676,184 853,862 1,174,932 1,004,226 1,448,641 STUDENT AFFAIRS 767,857 501,933 - 275,818 279,318 UNIVERSITY ADVANCEMENT 8,988,417 7,494,627 7,805,005 10,774,297 6,821,945 UNIVERSITY SERVICES 1,258,861 4,863,263 4,342,837 4,277,633 4,277,633 USF LAKELAND 179,111 414,614 229,597 251,588 210,863 USF SARASOTA/MANATEE - 700,333 1,316,778 334,229 133,102 USF ST. PETERSBURG 1,207,063 1,647,898 2,103,211 3,289,113 1,805,594 TOTAL$ 254,748,747 $ 290,108,101 $ 287,227,601 $ 310,150,152 $ 308,429,278 13 Office of Research Annual Report 2006/2007 Section 2 Awards Data CENTER AND INSTITUTE AWARDS FOUR-YEAR SUMMARY Centers/Institutes FY03/04 FY04/05 FY05/06 FY06/07 Center for Aging - Neuroscience$ 1,055,325 $ 1,446,504 $ 3,031,250 $ 2,112,011 Center for Biological Defense 5,159,492 4,379,313 4,289,023 2,117,048 Center for Economic Development Research 47,246 - - - Center for Health Outcomes Research 57,120 8,568 - - Center for Infant and Child Development 500,000 - - - Center for Leadership in Public Health Practice 1,049,792 27,000 1,129,555 1,331,165 Center for Molecular Delivery 217,500 247,038 - - Center for Ocean Technology 11,146,813 1,791,092 7,918,382 1,910,232 Center for Research on Children's Development & Learning - 3,348 - - Center for Robot Assisted Search and Rescue 676,445 398,696 767,880 3,292,147 Center for Urban Transportation Research 8,244,348 8,058,724 9,521,714 7,473,343 Center of Excellence - - - 8,000,000 Chiles Center, Lawton & Rhea 4,607,222 2,766,711 2,911,416
Load more

Recommended publications
  • PATENTES, DESENHOS INDUSTRIAIS, CONTRATOS, PROGRAMAS DE COMPUTADOR, INDICAÇÕES GEOGRÁFICAS O REVISTA DA PROPRIEDADE INDUSTRIAL N 1964 26 De Agosto De 2008
    PATENTES, DESENHOS INDUSTRIAIS, CONTRATOS, PROGRAMAS DE COMPUTADOR, INDICAÇÕES GEOGRÁFICAS o REVISTA DA PROPRIEDADE INDUSTRIAL N 1964 26 de Agosto de 2008 SEÇÃO I REPÚBLICA FEDERATIVA DO BRASIL Presidente Luís Inácio Lula da Silva MINISTÉRIO DO DESENVOLVIMENTO, INDÚSTRIA E COMÉRCIO EXTERIOR Ministro do Desenvolvimento, Indústria e Comércio Exterior Miguel João Jorge Filho INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL PRESIDENTE PARANÁ Jorge de Paula Costa Ávila Chefe: Renee Fernando Senger Pernambuco Rua Marechal Deodoro, 344, 16º andar Universitária Federal de Pernambuco - UFPE VICE-PRESIDENTE Ademir Tardelli Edifício Atalaia, Centro, Curitiba - PR Av. Prof. Moraes Rego, 1235 – Campus Universitário CEP: 80010-909 Bairro - Engenho do Meio CHEFE DE GABINETE Telefone/Fax: (0XX-41) 3322-4411 Recife - PE - CEP: 50670-920 Josefina Sales de Oliveira RIO GRANDE DO SUL Tel/Fax:(0XX-81) 3453-8145 e 3271-1223 Chefe: Vera Lúcia de Seixas Grimberg Piauí DIRETORIA DE ARTICULAÇÃO E INFORMAÇÃO TECNOLÓGICA Rua Sete de Setembro, 515 – 5º andar - Centro Av. João XXIII, n° 865 Marco Antônio Lima Porto Alegre - RS - CEP: 90010-190 Espaço Cidadania Telefone/Fax.: (0XX-51) 3226-6909 e 3226-6422 Teresina - PI - CEP: 64049-010 PROCURADORIA GERAL SÃO PAULO Tel.:(0XX-86) 3235-9616/3218-1838 Mauro Sodré Maia Chefe: Maria dos Anjos Marques Buso Fax:(0XX-86) 3218-1838 DIRETORIA DE PATENTES Rua Tabapuã, 41 - 4º andar - Itaim-Bibi Rio Grande do Norte Carlos Pazos Rodrigues São Paulo - SP - CEP: 04533-010 SECRETÁRIA DO DESENVOLVIMENTO ECONÔMICO – DIRETORIA DE MARCAS Telefone/Fax:
    [Show full text]
  • Immuno-Oncology Drug Development Workshop Hyatt Regency Washington on Capitol Hill Columbia A&B Ballroom Washington, DC October 13 - 14, 2016
    Immuno-Oncology Drug Development Workshop Hyatt Regency Washington on Capitol Hill Columbia A&B Ballroom Washington, DC October 13 - 14, 2016 Workshop Co-Chairs Maitreyee Hazarika, MD, Medical Officer, Division of Oncology Products 2, Office of Hematology Oncology Products, Center for Drug Evaluation and Research, FDA Dr. Hazarika is a Senior Medical Officer in the Melanoma and Sarcoma Team in the Division of Oncology Products 2 (DOP2) of the Office of Hematology and Oncology Products (OHOP) in the Center for Drug Evaluation and Research (CDER) of the United States Food and Drug Administration (FDA). As a regulatory reviewer, she has reviewed new molecular entities for marketing approvals in solid tumors and hematological malignancies, which have included immunotherapies, targeted kinase inhibitors, immunomodulators and folate analog metabolic inhibitors. She has presented FDA review findings as a speaker at oncology drug advisory committee meetings and has authored manuscripts presenting summaries on FDA drug approvals. In addition to the regulatory experience at FDA, she has experience in global clinical drug development while an Associate Medical Director, Clinical Development at Celgene International and also provided consulting services as a subject matter expert in oncology and on regulatory and clinical aspects of pharmaceutical drug development while a Principal Consultant at Parexel Consulting. Dr. Hazarika received her MBBS and MD degrees in India and completed her internship and residency in Internal Medicine and fellowship in Medical Oncology and Hematology at the New York University School of Medicine. As a fellow, she co-authored a book chapter while active in clinical research in ovarian cancer. Marc Theoret, MD, Lead Medical Officer, Division of Oncology Products 2, Office of Hematology Oncology Products, Center for Drug Evaluation and Research, FDA Dr.
    [Show full text]
  • Ste28.Pdf(469KB)
    Shiri Breznitz PhD Candidate, Dept. of Geography, University of Cambridge Email - [email protected] Research: My main focus is regional economic development. I am particularly interested in university-industry relationships and their influence on local economies. From Ivory Tower to Industrial Promotion: The Case of Yale University and the Biotechnology Cluster in New Haven, Connecticut Shiri Breznitz 28 Science, Technology and the Economy Program (STE) Working Papers Series STE-WP - 28 - 2005 From Ivory Tower to Industrial Promotion: The Case of Yale University and the Biotechnology Cluster in New Haven, Connecticut Shiri Breznitz Department of Geography University of Cambridge STE – WP 28 May 2005 This is a report on a research project conducted as part of the activities of the Science Technology and the Economy Program, (STE), at the Samuel Neaman Institute for Advanced Studies in Science and Technology. This research was carried out as part of a larger project on the Role of the University in Regional Economic Development. The author is grateful to the MIT Industrial Performance Center (IPC), the Cambridge Political Economy Society Trust, and the STE program at the Samuel Neaman Institute, for their generous support of this research. This paper presents the author’s own view and not that of the Samuel Neaman Institute for Advanced Studies in Science and Technology or any members of its staff. From Ivory Tower to Industrial Promotion: The Case of Yale University and the Biotechnology Cluster in New Haven, Connecticut Abstract In 2001 Ernst & Young ranked the state of Connecticut seventh in the nation with respect to the number of biotech firms operating within its borders relative to its population (Ernst & Young, 2001).
    [Show full text]
  • Orphan Drug Dummy File
    Orphan Drug Designations and Approvals List as of 09‐01‐2016 Governs October 1, 2016 ‐ December 31, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 1 1. Prevention of secondary carnitine deficiency in valproic acid toxicity 2. Treatment of secondary carnitine deficiency in Sigma-Tau levocarnitine Carnitor 11/15/1989 valproic acid toxicity Pharmaceuticals, Inc. 2 1. Treatment of graft versus host disease in patients receiving bone marrow transplantation 2. Prevention of graft versus host disease in patients receiving Pediatric thalidomide n/a 9/19/1988 bone marrow transplantation Pharmaceuticals, Inc. 3 A Diagnostic for the management Advanced Imaging Theranost 68 Ga RGD n/a 10/1/2014 of Moyamoya disease (MMD) Projects, LLC (AIP) 4 Cadila heat killed Mycobacterium w Pharmaceuticals immunomodulator Cadi Mw 9/3/2004 Active tuberculosis Limited, Inc. 5 Adjunct to cytokine therapy in the treatment of acute myeloid Histamine Ceplene 12/15/1999 leukemia. EpiCept Corporation 6 Adjunct to surgery in cases of rh-microplasmin, ocriplasmin Jetrea 3/16/2004 pediatric vitrectomy ThromboGenics Inc. 7 Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or Ferring Laboratories, Somatostatin Zecnil 6/20/1988 pancreas. Inc. Page 1 of 377 Orphan Drug Designations and Approvals List as of 09‐01‐2016 Governs October 1, 2016 ‐ December 31, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 8 Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with Allos Therapeutics, efaproxiral n/a 7/28/2004 breast cancer Inc.
    [Show full text]
  • Margin Stocks, Notice 97-22
    F e d e r a l R e s e r v e B a n k OF DALLAS ROBERT D. MCTEER, JR. _____ p r e s i d e n t DALLAS, TEXAS AND CHIEF EXECUTIVE OFFICER 75265-5906 March 10, 1997 Notice 97-22 TO: The Chief Executive Officer of each member bank and others concerned in the Eleventh Federal Reserve District SUBJECT Over-the-Counter (OTC) Margin Stocks DETAILS The Board of Governors of the Federal Reserve System has revised the list of over- the-counter (OTC) stocks that are subject to its margin regulations, effective February 10, 1997. Included with the list is a listing of foreign margin stocks that are subject to Regulation T. The foreign margin stocks listed are foreign equity securities eligible for margin treatment at broker- dealers. The Board publishes complete lists four times a year, and the Federal Register announces additions to and deletions from the lists. ATTACHMENTS Attached are the complete lists of OTC stocks and foreign margin stocks as of February 10, 1997. Please retain these lists, which supersede the complete lists published as of February 12, 1996. Announcements containing additions to and deletions from the lists will be provided quarterly. MORE INFORMATION For more information regarding marginable OTC stock requirements, please contact Eugene Coy at (214) 922-6201. For additional copies of this Bank's notice and the complete lists, please contact the Public Affairs Department at (214) 922-5254. Sincerely yours, yf f a * / ' . For additional copies, bankers and others are encouraged to use one of the following toll-free numbers in contacting the Federal Reserve Bank of Dallas: Dallas Office (800) 333 -4460; El Paso Branch Intrastate (800) 592-1631, Interstate (800) 351-1012; Houston Branch Intrastate (800) 392-4162, Interstate (800) 221-0363; San Antonio Branch Intrastate (800) 292-5810.
    [Show full text]
  • [ Emc-Lusinnufll'lergcrta'rgets
    US 20070255633Al (19) United States (12) Patent Application Publication (10) Pub. N0.: US 2007/0255633 A1 Kridel (43) Pub. Date: NOV. 1, 2007 (54) SYSTEMS AND METHODS FOR INVESTING (52) US. Cl. ....................................................... .. 705/35 (76) Inventor: FIVJigiam J. Kridel, New York, NY (57) ABSTRACT The present invention discloses systems and methods for Correspondence Address? creating and managing ?nancial instruments and indexes PAUL’ HASTINGS’ JANOFSKY & WALKER comprised of securities for companies in subsectors of the LLP economy. These ?nancial instruments alloW investment in R0' BOX 919092 subsectors of the economy Will still being able to minimize SAN DIEGO CA 92191-9092 ’ risk by diversi?cation. The indexes serve as benchmarks for (21) App1_ NO; 11/465,768 companies in the subsectors of the economy. A procedure may be used to identify the securities to include in the (22) Filed: Allg- 18, 2006 ?nancial instruments. This procedure may include (a) iden _ _ tifying securities for companies in a sector of the economy; Related U's‘ Apphcatlon Data (b) limiting the identi?ed securities to those for companies (60) Provisional application No. 60/778,492, ?led on Mar. in a SubSeCIOr Of the SBCIOI‘ Of the economy; (0) applying 1, 2006. focus rules to further limit the identi?ed securities to those _ _ _ _ for companies Who are focused in the subsector of the Pubhcatlon Classl?catlon economy; and (d) limiting the securities included in the (51) Int, Cl, ?nancial instrument or index to those that satisfy other G06Q 40/00 (2006.01) objective criteria. ETF RULE. SET->| APPLICATION’ ' "1 _.
    [Show full text]
  • Teligent Annual Report 2020
    Teligent Annual Report 2020 Form 10-K (NASDAQ:TLGT) Published: April 28th, 2020 PDF generated by stocklight.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-08568 TELIGENT, INC. (Formerly IGI Laboratories, Inc.) (Exact name of registrant as specified in its charter) Delaware 01-0355758 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 105 Lincoln Ave., Buena, New Jersey 08310 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code (856) 697-1441 Securities registered pursuant to Section 12(b) of the Exchange Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value Per Share TLGT The Nasdaq Stock Market Securities registered pursuant to Section 12(g) of the Exchange Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No x Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ¨ No x Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Shire R&A 01 Cover
    Shire Pharmaceuticals Group plc Shire Pharmaceuticals Group plc Annual review and summary financial statement 2001 Shire is proud of the part it plays in developing products which help people live their lives to the full. Shire, an international specialty pharmaceutical company, has a strategic focus on three therapeutic areas: central nervous system disorders, oncology and anti-infectives. It also has two platform technologies: advanced drug delivery and biologics. Our global sales and marketing infrastructure has an established product portfolio. Shire has its own marketing subsidiaries in the US, Canada, the UK and the Republic of Ireland, France, Germany, Italy and Spain, with plans to add Japan by 2004. We cover other pharmaceutical markets indirectly through distributors. Our interests in the Pacific Rim are managed through our regional office in Singapore. Shire has a risk-balanced R&D portfolio with clear focus on future product needs. Our global research and development expertise supported by in-licensing has, to date, successfully provided 20 marketed products, while the current pipeline of 24 projects includes 12 that are either in or post Phase II. To enhance the potential for future growth, Shire follows two approaches, firstly, to start projects in-house through research and advanced drug delivery and secondly to in-license projects and products on reasonable commercial terms, and then to develop and launch them. This broad approach strengthens Shire’s strategy and takes account of ongoing changes that are taking place in the industry. During the past seven years, we have completed six mergers and acquisitions and whereas we continue to evaluate M&A opportunities that offer a good strategic fit and add shareholder value, our priority is in-licensing more projects and products.
    [Show full text]
  • United States Securities and Exchange Commission Washington, D.C
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Under Rule 14a-12 IGI Laboratories, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. 1) Title of each class of securities to which transaction applies: 2) Aggregate number of securities to which transaction applies: 3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): 4) Proposed maximum aggregate value of transaction: 5) Total fee paid: ¨ Fee paid previously with preliminary materials. ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing: 1) Amount previously paid: 2) Form, Schedule or Registration Statement No: 3) Filing party: 4) Date Filed: IGI LABORATORIES, INC.
    [Show full text]
  • High Probability of Long-Term Survival in 2-Year Survivors of Autologous Hematopoietic Cell Transplantation for AML in first Or Second CR
    Bone Marrow Transplantation (2011) 46, 385–392 & 2011 Macmillan Publishers Limited All rights reserved 0268-3369/11 www.nature.com/bmt ORIGINAL ARTICLE High probability of long-term survival in 2-year survivors of autologous hematopoietic cell transplantation for AML in first or second CR NS Majhail1,2, R Bajorunaite3, HM Lazarus4, Z Wang3, JP Klein3, MJ Zhang3 and JD Rizzo3 1Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA; 2Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA; 3Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA and 4Division of Hematology and Oncology, University Hospitals Case Medical Center, Cleveland, OH, USA We describe the long-term outcomes of autologous Introduction hematopoietic cell transplantation (HCT) for 315 AML patients in first or second complete remission (CR). All After attainment of an initial remission, patients with AML patients were in continuous CR for X2 years after HCT. can receive consolidation therapy with either chemotherapy Patients were predominantly transplanted in CR1 (78%) or hematopoietic cell transplantation (HCT) based on and had good or intermediate cytogenetic risk disease various prognostic factors (for example, age, performance (74%). Median follow-up of survivors was 106 (range, status and cytogenetics). In general, patients with favorable 24–192) months. Overall survival at 10 years after HCT prognostic features receive consolidation chemotherapy was 94% (95% confidence intervals, 89–97%) and 80% only, whereas those with high-risk disease and an (67–91%) for patients receiving HCT in CR1 and CR2, acceptable risk of treatment-related morbidity and mortality respectively. The cumulative incidence of relapse at 10 are offered allogeneic HCT.
    [Show full text]
  • Orphan Drug Designations and Approvals List As of 12-02-2013 Governs January 1, 2014
    Orphan Drug Designations and Approvals List as of 12‐02‐2013 Governs January 1, 2014 ‐ March 31, 2014 Row Designation Generic Name Trade Name Orphan Designation Contact Company/Sponsor Num Date Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B‐cell Lymphoma of Mucosa‐ Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B‐cell Non‐Hodgkin's 1 bendamustine hydrochloride Treanda 11/26/2013 Lymphoma) Cephalon, Inc. Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear 2 Filgrastim Neupogen 11/20/2013 incident Amgen, Inc. adeno‐associated viral vector containing the human NADH Treatment of Leber Hereditary 3 Dehydrogenase 4 Gene n/a 11/20/2013 Optic Neuropathy Gen Sight Biologics Treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and 4 emricasan n/a 11/20/2013 end stage liver disease Conatus Pharmaceuticals Inc. Page 1 of 262 Orphan Drug Designations and Approvals List as of 12‐02‐2013 Governs January 1, 2014 ‐ March 31, 2014 5‐((4‐bromo‐2‐ fluorophenyl)amino)‐4‐fluoro‐N‐(2‐ hydroxyethoxy)‐1‐methyl‐1H‐ Treatment Stage IIB‐IV Novartis Pharmaceuticals 5 benzo[d]imidazole‐6‐carboxamide n/a 11/19/2013 melanoma. Corporation Treatment of Hepatitis Delta 6 Lonafarnib n/a 11/19/2013 Virus (HDV)infection Eiger Biopharmaceuticals, Inc. Treatment in Stage IIB‐IV melanoma positive for the Novartis Pharmaceuticalues 7 MEK162
    [Show full text]
  • New Medicines in Development for Cancer Pharmaceutical Research and Manufacturers of America (Phrma) Drugs Are Listed Alphabetically Within Disease Category
    Pharmacy Practice New Medicines in Development for Cancer Pharmaceutical Research and Manufacturers of America (PhRMA) Drugs are listed alphabetically within disease category. Note: Selected agents have been chosen based on Phase III and IV status. † 354 NEW WEAPONS ARE IN DEVELOPMENT ME D I C I N E S I N D E V E L O P M E N T F O R C A N C E R * FOR THE WAR ON CANCER Can we declare victory in the war on cancer? “Wars are never won just like that – they’re a series of battles and skirmishes,” says cancer re s e a rcher Dr. Derek Raghavan of the University of California at Los Angeles. “If this were World War II, this would be 1943. We ’ r e about three quarters of the way there . ” Pharmaceutical re s e a r ch, by developing formidable weapons against cancer, has played a key role in the p r o g r ess against this disease. And a new survey found 354 additional medicines in development for cancer. The medicines include 63 for breast cancer, which strikes one out of every 10 American women; 58 for skin cancer including melanoma, the most serious form of skin cancer, whose incidence has grown 4 percent a year since the 1970s; 58 for lung cancer, the leading cause of cancer death in the US; and 46 for colon cancer, the second leading cancer killer of both men and women. These medicines in development *Some medicines are listed in more than one category.
    [Show full text]